Restart Life Sciences Corp.
HEAL
CNSX
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 461.70K | 203.50K | 87.20K | 61.10K | 100.90K |
Depreciation & Amortization | 300.00 | 400.00 | 400.00 | 400.00 | 400.00 |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 465.50K | 203.90K | 87.70K | 61.50K | 101.70K |
Operating Income | -465.50K | -203.90K | -87.70K | -61.50K | -101.70K |
Income Before Tax | -570.50K | 100.00 | 336.90K | -66.20K | -107.10K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -570.50K | 100.00 | 336.90K | -66.20K | -107.10K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -570.50K | 100.00 | 336.90K | -66.20K | -107.10K |
EBIT | -465.50K | -203.90K | -87.70K | -61.50K | -101.70K |
EBITDA | -465.10K | -203.50K | -87.20K | -61.10K | -101.30K |
EPS Basic | -0.02 | 0.00 | 0.02 | 0.00 | -0.01 |
Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
EPS Diluted | -0.02 | -0.01 | 0.01 | 0.00 | -0.01 |
Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
Average Basic Shares Outstanding | 26.73M | 16.67M | 14.83M | 14.81M | 14.81M |
Average Diluted Shares Outstanding | 26.73M | 18.50M | 15.32M | 14.81M | 14.81M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |